Press release
Mar 8, 2012

Sosei Announces Initiation of Phase I study for SO-1105


Tokyo, Japan – 8 March 2012: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis. SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in October 2006. SO-1105 has since been registered in 26 European countries, in South Korea, and in the United States, under the trade names Loramyc®/Oravig®.

The clinical study will be conducted in a single study centre in Japan, and is designed to evaluate the pharmacokinetics and safety of SO-1105 in healthy Japanese adults.

SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. SO1105 has the potential to become the first long-acting, sustained-release treatment in tablet form for oropharyngeal candidiasis in Japan that could enhance patients’ compliance and quality of life.

Shinichi Tamura, CEO of Sosei Group Corporation, commented: "This is an important step forward in development of SO-1105. We will continue with our efforts to bring SO-1105 to the Japanese market, as it has the potential to provide meaningful benefits to OPC patients compared to existing treatments.” 


 DOWNLOAD PDF